Vivolux AB was founded in 2006, based on substances developed in-house and in collaboration with a research group in Uppsala that has developed an advanced system for preclinical analysis of cancer drugs based on tests using fresh human cancer cells. Collaboration was later established with Stig Linder's research group at the Karolinska Institute. This collaboration has resulted in access to a further unique method for evaluating the effects of cancer drugs. In contrast to the standard method, which is used by leading pharmaceutical companies, three-dimensional aggregates of human cancer cells are used as models of solid tumors. This facilitates identification and optimization of drug candidates that can reach and kill all cells deep in the tumor tissue. With the aid of these unique methods, several drug candidates have been identified and optimized.